Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Rating of “Buy” from Brokerages

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) have earned a consensus rating of “Buy” from the eight ratings firms that are covering the company, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have issued a report on the stock in the last year is $12.13.

A number of equities research analysts have commented on STRO shares. Truist Financial reduced their price target on shares of Sutro Biopharma from $18.00 to $15.00 and set a “buy” rating for the company in a report on Friday, August 16th. Piper Sandler restated an “overweight” rating and issued a $11.00 target price on shares of Sutro Biopharma in a research note on Friday, October 11th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Sutro Biopharma in a research note on Friday, October 11th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $17.00 price target on shares of Sutro Biopharma in a report on Monday, September 16th.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. ProShare Advisors LLC grew its holdings in Sutro Biopharma by 49.1% during the second quarter. ProShare Advisors LLC now owns 16,316 shares of the company’s stock worth $48,000 after buying an additional 5,373 shares in the last quarter. Lazard Asset Management LLC bought a new stake in shares of Sutro Biopharma in the 1st quarter worth $92,000. The Manufacturers Life Insurance Company grew its stake in shares of Sutro Biopharma by 27.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 32,943 shares of the company’s stock worth $97,000 after acquiring an additional 7,082 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Sutro Biopharma by 24.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 18,027 shares of the company’s stock valued at $102,000 after purchasing an additional 3,578 shares during the last quarter. Finally, SG Americas Securities LLC lifted its position in shares of Sutro Biopharma by 134.6% during the third quarter. SG Americas Securities LLC now owns 34,662 shares of the company’s stock valued at $120,000 after purchasing an additional 19,890 shares in the last quarter. Institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Price Performance

Shares of NASDAQ:STRO opened at $3.55 on Friday. Sutro Biopharma has a 1 year low of $2.01 and a 1 year high of $6.13. The business’s 50-day moving average is $3.87 and its 200-day moving average is $3.81. The company has a market capitalization of $290.96 million, a price-to-earnings ratio of -1.94 and a beta of 1.17.

Sutro Biopharma (NASDAQ:STRO) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.20. The firm had revenue of $25.71 million for the quarter, compared to analysts’ expectations of $26.28 million. Sutro Biopharma had a negative return on equity of 102.06% and a negative net margin of 73.48%. Analysts anticipate that Sutro Biopharma will post -2.96 EPS for the current year.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.